LMWH and anticoagulants in Morocco: Novex (enoxaparin) guide

01Understanding LMWHs#

Important medical notice. Any initiation, modification or discontinuation of anticoagulant treatment must be validated by your physician or attending cardiologist.

Low molecular weight heparins (LMWHs) have become the standard of care for the prevention and treatment of venous thromboembolic disease (VTE) in Morocco, having progressively displaced unfractionated heparin in most indications. These molecules act mainly on activated factor X (Xa), with weaker activity against thrombin. For enoxaparin, the plasma half-life is approximately 4 to 5 hours, but the anti-Xa activity half-life reaches 12 hours, which justifies the twice-daily rhythm used in most curative protocols.

In Morocco, the DMP has approved: enoxaparin (Lovenox Sanofi, generic Novex Sothema), and nadroparin (Fraxiparine). Tinzaparin and dalteparin are not listed in the Moroccan BNDM/ANAM database.

Cardiologists prescribe an LMWH in several settings: major orthopaedic surgery prophylaxis (total hip replacement, total knee replacement), curative treatment of DVT or PE, prevention in the bedridden medical patient, and acute coronary syndrome (ACS). In NSTEMI, enoxaparin is given at 1 mg/kg every 12 hours SC. In STEMI (ESC 2020 guidelines): IV bolus 30 mg followed by 1 mg/kg/12h SC, with adjustment in patients over 75 years to 0.75 mg/kg/12h SC without bolus.

LMWHs are not the long-term treatment for non-valvular atrial fibrillation (where DOACs or VKAs are used according to the CHA2DS2-VASc score), nor for mechanical heart valves (VKAs only). The distinction matters in everyday Moroccan practice because many patients arrive at the cardiology clinic with an enoxaparin prescription described as "lifelong", a frequent bridging error after hospitalisation for a coronary event or paroxysmal atrial fibrillation. Enoxaparin remains either a bridging therapy or a time-limited acute treatment, never a chronic strategy except in specific scenarios such as cancer-associated VTE, where CHEST 2021 and ASCO 2023 guidelines place LMWH as first-line therapy for 3 to 6 months before any consideration of a switch to a DOAC.

02Anti-Xa pharmacokinetics and pharmacological profile#

Understanding enoxaparin's pharmacokinetics helps explain to the patient why a twice-daily rhythm exists, why the peak is measured at H+4 and why the subcutaneous route has replaced the intravenous one for the vast majority of clinical situations. After subcutaneous injection, bioavailability is approximately 92 to 95% according to the pharmacokinetic studies published by the European Medicines Agency (EMA) in the Lovenox SmPC (Summary of Product Characteristics). This nearly complete absorption explains the predictability of the anti-Xa response, which is markedly superior to that of unfractionated heparin (UFH), whose SC bioavailability does not exceed 30%.

The peak anti-Xa activity occurs between 3 and 5 hours after injection, which determines the timing of sampling for the rare situations in which anti-Xa monitoring is indicated (moderate renal impairment, obesity with BMI > 40, pregnancy, paediatrics). The plasma half-life of 4 to 5 hours combined with the anti-Xa activity half-life of approximately 12 hours justifies the 12-hour interval in curative regimens. This dissociation between plasma half-life and activity half-life is explained by the binding of heparin chains to antithrombin III, which prolongs the pharmacological effect beyond simple circulating presence.

Elimination is predominantly renal (40%), which is why systematic dose adaptation is required in patients with impaired renal function. The remainder undergoes hepatic catabolism with enzymatic breakdown of the saccharide chains. Unlike VKAs, enoxaparin does not interact with the cytochrome P450 system, which drastically reduces the number of pharmacokinetic drug-drug interactions compared with warfarin or acenocoumarol (Sintrom). The clinically significant interactions are therefore pharmacodynamic (additive antithrombotic effect) rather than metabolic.

03Novex and the enoxaparin range in Morocco#

Novex is the Moroccan generic enoxaparin sodium produced by Sothema. Presentations available in Moroccan pharmacies: Novex 2000 IU anti-Xa/0.2 ml, Novex 4000 IU/0.4 ml, Novex 6000 IU/0.6 ml, Novex 8000 IU/0.8 ml. Product pages: Novex 2000, Novex 4000, Novex 6000.

The fundamental conversion rule: 100 IU anti-Xa = 1 mg enoxaparin sodium. So Novex 4000 IU = 40 mg, 6000 IU = 60 mg, 10 000 IU = 100 mg. This equivalence is essential for reading prescriptions and calculating weight-based doses correctly.

04LMWHs, UFH, DOACs and fondaparinux: choosing the right molecule#

The family of parenteral and oral anticoagulants has expanded considerably over the past fifteen years, and the choice of molecule now depends on the clinical context, comorbidities and the foreseeable duration of treatment. Unfractionated heparin (UFH) remains indicated in patients with severe renal impairment (CrCl < 15 ml/min), during cardiac surgery under cardiopulmonary bypass, when mechanical valves are being implanted, and whenever immediate reversibility with protamine sulfate is required (protamine neutralises UFH by close to 100%, compared with around 60% for LMWHs). UFH requires monitoring of the aPTT every 4 to 6 hours, a heavy in-hospital constraint compared with the autonomy offered by enoxaparin.

Direct oral anticoagulants (DOACs) — rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Lixiana) — have transformed the management of stable VTE and non-valvular atrial fibrillation. In Morocco, their price remains a real barrier: one month of apixaban 5 mg costs roughly 700 to 900 MAD, compared with 300 to 400 MAD for one month of prophylactic enoxaparin. The basic AMO scheme (Assurance Maladie Obligatoire, Morocco's mandatory state health insurance run by ANAM) has partially reimbursed DOACs since 2024 for atrial fibrillation indications validated by a cardiologist, but the patient co-payment remains significant. DOACs are preferred to enoxaparin for long-term maintenance treatment of non-cancer-associated VTE, given the oral route and the absence of routine biological monitoring.

Fondaparinux (Arixtra) is a synthetic pentasaccharide that selectively inhibits factor Xa, with no activity against thrombin IIa. It retains a place of choice in the management of NSTEMI with no immediate interventional risk (OASIS-5 trial) and constitutes the reference anticoagulant switch when HIT has been confirmed, since its synthetic structure rules out any cross-reactivity with anti-PF4-heparin antibodies. In Morocco, Arixtra 2.5 mg is available, but its price (approximately 180 to 220 MAD per syringe) limits its use to the acute in-hospital phase.

05Adjusting dose to weight, renal function and patient profile#

Major orthopaedic surgical prophylaxis: 4000 IU once daily SC, post-operative initiation (12 hours after surgery). Duration: 10 to 14 days minimum for TKR, 35 days for THR or femoral neck fracture.

General surgery, moderate risk: 2000 IU once daily for 7-10 days. Oncological surgery: 4000 IU/day for 4 weeks.

Medical prophylaxis: 4000 IU once daily for 6-14 days, particularly in bedridden patients with additional risk factors.

Curative treatment of DVT or PE: 100 IU/kg (1 mg/kg) every 12 hours SC — this is the standard regimen. An alternative regimen of 150 IU/kg once daily is reserved for uncomplicated VTE without additional risk factors.

Renal impairment: clearance calculated with the Cockcroft-Gault formula. Creatinine clearance 15-30 ml/min: curative → 100 IU/kg once daily; prophylactic → 2000 IU once daily. ClCr < 15 ml/min: absolute contraindication (alternative: intravenous unfractionated heparin).

Obesity and extreme body weights: the curative dose is calculated on actual body weight up to roughly 144 kg for enoxaparin, with no systematic ceiling. Beyond that, or as soon as the BMI exceeds 40, the French Society of Anaesthesia and Intensive Care (SFAR) recommendations and the CHEST 2021 guidelines advise measurement of peak anti-Xa activity (H+4 after the third injection) to confirm a therapeutic window of 0.5 to 1 IU/ml in curative regimens. Symmetrically, patients weighing less than 50 kg carry a heightened bleeding risk: cautious dose adaptation with anti-Xa monitoring, and the curative dose may sometimes be reduced to 0.75 mg/kg/12h after consultation with the cardiologist or haematologist.

06Pregnancy and breastfeeding: LMWHs as the reference treatment#

LMWHs are the reference anticoagulant during pregnancy. Enoxaparin does not cross the placenta and is not teratogenic. Indications: history of DVT or PE, antiphospholipid syndrome (APS), inherited thrombophilias, pregnancy-related VTE, and post-caesarean prophylaxis in at-risk women.

Prophylactic doses: 4000 IU/day. Curative doses: 100 IU/kg every 12 hours with anti-Xa monitoring (target 0.5-1 IU/ml, peak 4 hours after injection).

During breastfeeding: milk transfer is negligible, infant oral absorption is zero, so compatibility is total.

07Paediatrics#

Doses: 150 IU/kg/12h in infants under 2 months, 100 IU/kg/12h thereafter, with systematic anti-Xa monitoring. Use is strictly hospital-based and specialist-supervised.

08Absolute contraindications#

• Hypersensitivity to enoxaparin, heparin or protamine.
• History of HIT type II within the last 100 days.
• Active significant bleeding.
• Recent haemorrhagic stroke.
• Acute infective endocarditis.
• ClCr < 15 ml/min (outside of supervised dialysis settings).
• Neuraxial anaesthesia for curative doses.
• Active peptic ulcer, bleeding oesophageal varices.

Spinal haematoma: reinforced ANSM/FDA boxed warning

• Prophylactic LMWH: neuraxial puncture at least 12 hours after the last injection.
• Curative LMWH: puncture at least 24 hours after the last injection.
• Resumption of LMWH: at least 4 hours after the puncture.

09Subcutaneous injection technique#

Site: anterolateral abdominal belt, at least 5 cm from the navel, alternating sides. Disinfect with alcoholic chlorhexidine and wait 30 seconds.

Air bubble: for non-graduated syringes (full dose), the bubble must never be purged because it ensures the entire dose is delivered. For graduated syringes (especially 6000, 8000, 10 000 IU or high-concentration formats), the excess must be purged, with the needle tip pointing upwards, down to the graduation corresponding to the prescribed dose.

Skin fold pinched between thumb and index finger, needle held perpendicular at 90°, slow injection over 10-15 seconds without aspiration. No massage after withdrawal of the needle.

Disposal of needles: DASRI sharps container purchased at the pharmacy. In Morocco, there is no free national collection circuit comparable to the French DASTRI scheme.

10Platelet monitoring and heparin-induced thrombocytopenia (HIT)#

Frequency of HIT type II under LMWH: 0.1 to 1% after 5 days, with the peak between D5-D14. Baseline platelet count at D0 then twice weekly for 21 days in high-risk situations.

Drop > 50% or absolute count below 100 000/mm³ → suspect HIT, immediate discontinuation. The 4T score assesses: Thrombocytopenia, Timing, Thrombosis, oTher causes. Switch to fondaparinux (Arixtra, available in Morocco), argatroban or danaparoid (not marketed in Morocco, requiring nominative import under ATU procedure).

11Bleeding risk and protamine sulfate#

Serious warning signs: digestive bleeding (bloody vomiting, melaena), gross haematuria, sudden headache with neurological signs, unexplained acute abdominal pain, shortness of breath with hypotension.

Aggravating factors: age over 75 years, severe renal impairment, weight under 50 kg, recent peptic ulcer, combination with: aspirin, clopidogrel, prasugrel, ticagrelor, NSAIDs, VKAs, DOACs, SSRIs and SNRIs, systemic corticosteroids, dextran, fibrinolytics (contraindicated combination), St John's wort and Ginkgo biloba.

Protamine sulfate: a partial antidote

• 1 mg of protamine per 100 IU anti-Xa if the last injection was less than 8 hours ago.
• 0.5 mg per 100 IU if 8-12 hours.
• Beyond 12 hours: symptomatic management only.
• Maximum 50 mg per bolus, infused slowly over at least 10 minutes (risk of sudden hypotension, anaphylaxis, bradycardia).

12Prices in Morocco and AMO coverage#

Indicative 2026 price ranges for Novex: 2000 IU 45-55 MAD, 4000 IU 75-90 MAD, 6000 IU 105-125 MAD, 8000 IU 135-160 MAD. Original-brand Lovenox is appreciably more expensive (approximately 30 to 45% above the generic depending on the strength). A box of Novex 4000 IU with ten pre-filled syringes, the most widely dispensed format for ambulatory prophylaxis, costs approximately 150 to 180 MAD at the pharmacy.

The basic AMO scheme run by ANAM (Assurance Maladie Obligatoire administered by the Agence Nationale de l'Assurance Maladie) was generalised between 2022 and 2024 under framework law 09-21. Funds: CNOPS (Caisse Nationale des Organismes de Prévoyance Sociale, covering the public sector) and CNSS (Caisse Nationale de Sécurité Sociale, covering the private sector), with reimbursement rates set by ANAM conventions. In practical terms in 2026, enoxaparin is reimbursed at 80% of the National Reference Tariff when prescribed in the setting of a scheduled orthopaedic or oncological surgery, on a hospital prescription. Reimbursement is lower (50 to 70%) for ambulatory prescriptions outside the long-term affection scheme. Established VTE, when it qualifies for long-term affection (ALD) cover under ALD 30 cardiovascular as recognised by ANAM, allows reimbursement of 90% or even 100% depending on the convention. Severe psoriasis, lupus with antiphospholipid syndrome and active cancer may also open an ALD that frames the cost of LMWHs.

For patients without insurance cover, the monthly cost of curative treatment in a 70 kg adult receiving 70 mg twice daily easily exceeds 1 200 to 1 500 MAD per month, which raises a major adherence concern. Discussing an early switch to a DOAC where eligibility allows, or being clear with the prescribing physician about the minimum recommended duration, helps avoid hasty interruptions with serious thromboembolic consequences.

13Bridging to VKAs and DOACs: practical rules#

The switch from a curative LMWH to a vitamin K antagonist (VKA) — in Morocco primarily acenocoumarol (Sintrom 4 mg) and fluindione (Previscan) — follows a codified protocol. Both molecules are co-administered for at least 5 days AND until an INR within the 2.0 to 3.0 therapeutic range has been obtained on two consecutive measurements 24 hours apart. Premature withdrawal of the LMWH before the therapeutic INR has been reached exposes the patient to a dangerous thrombogenic window, particularly in the cancer patient or the carrier of antiphospholipid syndrome. Therapeutic education for the Moroccan patient must emphasise the regularity of INR testing, ideally performed at a local laboratory with results returned within 4 hours.

The LMWH to DOAC bridge is more straightforward: enoxaparin is stopped and the DOAC is started at the time at which the next injection would have been due, without overlap. Rivaroxaban and apixaban have specific initial-treatment protocols for VTE (rivaroxaban: 15 mg twice daily for 21 days then 20 mg once daily; apixaban: 10 mg twice daily for 7 days then 5 mg twice daily) that make the transition predictable. Conversely, the bridge from a DOAC to an LMWH (often decided in the peri-operative setting of a scheduled procedure) requires the DOAC to be stopped 24 to 48 hours before the surgical procedure depending on the molecule and renal function, and prophylactic enoxaparin to be started on the evening of the operation.

14Storage, travel and everyday life#

Unlike VKAs, LMWHs require no dietary restriction. Moderate physical activity is encouraged. Contact sports with traumatic risk should be avoided.

Storage: the Lovenox SmPC indicates storage below 25 °C, no freezing, no mandatory refrigeration. For Novex, the official Moroccan leaflet should be checked.

Air travel is allowed. Syringes can be carried in cabin baggage with a prescription and a medical certificate in French or English.

During Ramadan, most LMWH regimens can be administered as a single evening dose after iftar.

Independent home-nurse fee: 40 to 80 dirhams per visit, varying with city.

15Long-haul air travel and DVT prevention#

The so-called "economy-class syndrome", long under-recognised, has been the subject of a dedicated information sheet from the World Health Organization and the French Haute Autorité de Santé (HAS) since 2018. The relative risk of DVT is multiplied by 2 to 3 for flights longer than 4 hours, and by 5 to 10 for flights longer than 8 hours in at-risk individuals (personal or family history of VTE, active cancer, post-partum status, recent combined oral contraception, obesity, prior immobilisation). For Moroccan expatriates (MRE — Marocains Résidant à l'Étranger) flying Casablanca-Montreal (8 hours), Casablanca-Dubai (7 hours) or Casablanca-Beijing (12 hours), pre-departure risk stratification is essential.

In low to moderate risk, simple measures are sufficient: regular hydration (a large glass of water every hour), ankle mobilisation every 30 minutes, walking in the cabin at least every 2 hours, and avoidance of alcohol and sedatives that prolong immobility. Wearing class 2 compression stockings (15-20 mmHg pressure at the ankle) is recommended for any flight of more than 4 hours in moderately at-risk patients; in Morocco, these stockings are available at pharmacies and orthopaedic supply stores at an average price of 180 to 350 MAD per pair.

In high-risk individuals — recent VTE history, active cancer, major surgery within the previous 4 weeks, pregnancy with thrombogenic risk — a single injection of enoxaparin 4000 IU administered 2 to 4 hours before take-off is recommended for flights longer than 6 hours, on prescription from the cardiologist or attending physician. Storage during the flight is rarely a problem (cabin temperatures remain stable), but it is prudent to carry a bilingual prescription (French-English) together with a medical certificate to present at customs and airport security.

16Common errors to avoid in everyday practice#

Several recurring errors at the pharmacy counter and at home account for a non-negligible share of the bleeding and thrombotic complications observed under LMWH. The first is confusion between milligrams and units: a patient prescribed "40 mg" must receive Novex 4000 IU, and not 0.4 ml from a Novex 6000 IU syringe, a frequent mental-dilution error when the appropriate strength is unavailable in the pharmacy. The rule remains immutable: 1 mg = 100 IU anti-Xa.

The second error concerns the incomplete rotation of injection sites: the patient injects in the same spot day after day, producing superficial haematomas, subcutaneous induration and occasionally localised cutaneous necrosis (Cohen reaction, rare but documented in the literature). Dividing the abdomen mentally into four quadrants and rotating systematically resolves the problem.

The third error is purging the air bubble of non-graduated full-dose syringes. This unnecessary purge causes a loss of 5 to 10% of the actually injected dose, enough to leave a high-risk patient under-dosed in prophylaxis. Conversely, failing to purge the excess from a graduated syringe leads to overdosing, particularly hazardous in renal impairment.

The fourth error is the abrupt discontinuation on returning home after orthopaedic surgery: 12 to 18% of Moroccan patients, lacking telephone follow-up, stop enoxaparin after 7 days following a total hip replacement, for which the recommended duration is 35 days. The result is late-onset DVT (D20-D28), potentially embolising and a classic cause of rehospitalisation. Discharge education, ideally reinforced by a nursing telephone call at D7 and D21, halves this premature discontinuation rate according to data from the Ibn Rochd University Hospital cohort published in 2024.

Finally, self-prescription in patients who reuse an old prescription for a new episode of calf pain without diagnostic confirmation by venous duplex ultrasound. Calf pain corresponds to a DVT in only around 30% of suspected cases; the remaining 70% encompass muscle injuries, Baker's cysts, sciatica and superficial venous insufficiency, situations in which enoxaparin is useless or even harmful. The reflex to promote among sahha.ma readers remains: any suspicion of DVT mandates a venous duplex ultrasound within 24 hours before any curative anticoagulation is started.

17When to seek emergency care#

Any uncontrolled visible bleeding persisting after 15 minutes of compression. Signs of internal haemorrhage: sudden headache, visual disturbance, paralysis, speech disturbance, severe abdominal pain, bloody vomiting, black tarry stools, red urine. Sudden chest pain or acute dyspnoea under curative treatment → possible pulmonary embolism. Asymmetric swelling of a lower limb.

Skin rash, unexplained fever → allergic reaction or early HIT. Fall in an elderly patient on LMWH → consult promptly to rule out a deep haematoma.

Reminder. This article is informational and does not replace medical consultation.